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AbstrAct
background: This study presents a retrospective analysis (efficacy and toxicity) of outcomes in patients with unresectable 
recurrence of previously irradiated head and neck (h&N) cancers treated with proton therapy. Locoregional recurrence is the 
main pattern of failure in the treatment of h&N cancers. proton re-irradiation in patients with relapse after prior radiotherapy 
might be valid as promising as a challenging treatment option. 
Materials and methods: From November 2015 to January 2020, 30 patients with in-field recurrence of head and neck cancer, 
who were not suitable for surgery due to medical contraindications, tumor localization, or extent, received re-irradiation with 
intensity-modulated proton therapy (IMpT). sites of retreatment included the aerodigestive tract (60%) and the base of skull 
(40%). The median total dose of prior radiotherapy was 55.0 Gy. The median time to the second course was 38 months. The me-
dian re-irradiated tumor volume was 158.1 cm3. patients were treated with 2.0, 2.4, and 3.0 GyrBe per fraction, with a median 
equivalent dose (eQD2) of 57.6 Gy (a/b = 10). radiation-induced toxicity was recorded according to the rTOG/eOrTc criteria. 
results: The 1- and 2-year local control (Lc), progression-free survival (pFs), and overall survival (Os) were 52.6/21.0, 21.9/10.9, 
and 73.4/8.4%, respectively, with a median follow-up time of 21 months. The median overall survival was 16 months. acute 
grade 3 toxicity was observed in one patient (3.3%). There were five late severe side effects (16.6%), with one death associated 
with re-irradiation. 
conclusion: re-irradiation with a proton beam can be considered a safe and efficient treatment even for a group of patients 
with unresectable recurrent h&N cancers.  
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Head and neck (H&N) cancers are among the 
most common cancers, accounting for more than 
500,000 new cases, with around 300.000 deaths 
each year [1]. Despite treatment intensification in 
the last decades, the 5-year overall survival still 
varies between 40% to 50% [2]. Most patients 
have a high risk of locoregional recurrence or sec-
ond metachronous tumors occurring marginal or 
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close to previously irradiated volume [3, 4]. Sur-
gery as a salvage option for relapse is considered 
to be highly efficient, with 5-year overall survival 
approaching 40% [5]. Surgery can provide addi-
tional benefit by removing radio- and chemore-
sistant tumor cells that create a higher possibility 
of a combined cure. However, many patients are 
not candidates for surgical approaches because of 
the recurrent tumor extent or medical contrain-
dications [6, 7]. With chemotherapy alone, which 
has been the most common option for inoperable 
patients, the response rate is relatively low, limited 
to a median survival time of 7–8 months [8]. Re-ir-
radiation with conventional or hypofractionation 
(SBRT) showed promising results as a potentially 
curative treatment, although increasing severe tox-
icities rates up to 40% [9, 10]. 
While locoregional failure after the second ra-
diotherapy (RT) course is still common, some pa-
tients might be irradiated again. It has become criti-
cally important to spare normal tissue as much as 
possible, owing to its impact on the quality of life 
(QoL) and further treatment.   
Since recurrence treatment goals are not only to 
cure the patient but also to provide acceptable QoL, 
proton therapy (PT) becomes more frequently used 
as a re-irradiation approach over the last decades 
[11]. Dosimetric and radiobiological advantages of 
protons offer better organs at risk sparing and may 
benefit previously irradiated patients. 
In this study, we present a proton therapy with 
pencil beam results for the second irradiation of 
in-field recurrence of head and neck cancer in pa-
tients who were not eligible to undergo surgery nei-
ther before nor after PT, due to comorbidity and/or 
tumor extent. Disease control, treatment-related 
toxicity, and influencing factors were analyzed. 
Materials and methods
A group of 30 patients treated for a local recur-
rence of H&N cancer with a proton beam to a pre-
viously irradiated site, between November 2015 and 
January 2020, was approved for retrospective analy-
sis by a local institutional review board, including 
waivers of informed consent due to the retrospec-
tive nature of the study. All patients were more than 
18 years old, with biopsy-confirmed diagnosis, both 
at initial treatment and recurrence, with a period 
from a prior RT of at least six months, and without 
signs of severe (grade 3–4) persistent toxicity. All 
patients included in the study had a minimum of 
3 months of follow-up time. Before the treatment, 
the patient’s medical history and current possible 
options were discussed at the multidisciplinary tu-
mor board. 
The second RT course was delivered via a fixed 
horizontal, spot-scanning proton beam, in a seated 
position [12]. A daily image-guidance was per-
formed with built-in cone-beam computer tomog-
raphy (CB-CT). Simulation CT was obtained with-
out intravenous contrast, with a 1-mm slice thick-
ness. The patient was immobilized using a standard 
thermoplastic mask. Both MRI with contrast and 
18FDG-PET/CT scans in a non-treatment position 
were obligatorily fused. 
If it was possible, previous RT-plans were reg-
istered in the treatment planning system (TPS) 
to the new CT. The problem of radiation therapy 
in Post-Soviet states is that there are still hospi-
tals providing treatment with the 2D technique, 
via non-multileaf collimator linear accelerators or 
60Co-units. So, some of our patients received con-
ventional RT. In such a situation, field setup and 
treatment parameters were reconstructed in TPS, 
according to the patient’s RT medical records.  
The gross tumor volume (GTV) was delineated 
by a combination of a tumor recognized on MR-im-
ages and 18FDG-PET/CT scans, co-registered to the 
simulation CT. Additionally, we reduced a clinical 
volume (CTV) to a 5-mm margin adapted to the 
patient’s CT anatomy by using molecular imaging. 
For the planning target volume (PTV) generation, 
the corresponding CTV was expanded by a 3-mm 
margin to the skull base site, and by 5 mm in the 
case of the aerodigestive tumor localization, for 
covering setup uncertainties.   
As almost half of our patients had previously 
received conventional radiotherapy, it was risky to 
relay reconstructed doses to OARs completely. So, 
the strategy for critical structures sparring was to 
reduce the dose as much as achievable [13]. 
The total doses in the case of prior conformal 
RT to the OARs were based on QUANTEC group 
articles and calculated to its biologically effective 
dose (BED) (a/b = 3) to estimate the risk of toxici-
ties in the normal tissues. Serial OARs (i.e., spinal 
cord, optic nerves, chiasma, and brain stem) were 
allowed to receive a cumulative dose < 120–125% 
from its QUANTEC-proposed tolerance, as nerve 
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tissue was shown to recover 20–25% tolerance after 
one year from RT [14]. 
Proton therapy (PT) was delivered once a day, 
five times per week, by the intensity modulation 
technique, always supported with CB-CT imaging 
before each field. PT dose was prescribed to the 
PTV with a goal of at least 95%. According to the 
re-irradiation nature and additional CTV margin 
presence, OAR dose constraints took priority over 
PTV coverage, in instances where both were not 
achievable. Relative biological effectiveness (RBE) 
of 1.1 for protons was assumed. Patients were treat-
ed with 2 (n = 3), 2.4 (n = 9) and 3 GyRBE (n = 18) 
per fraction, with the median EQD2 (a/b = 10) of 
57.6 Gy [range, 42.1 to 68.0]. Fractionation sched-
ules were based on a tumor volume and a patient’s 
performance status. 
Adjuvant systemic therapy was delivered by the 
prescriptions of the treating medical oncologist. 
All patients were screened first in 4–6 weeks after 
finishing PT, and then every three months, unless 
the patient has required another frequency due to 
progression or severe toxicity. Both MR imaging 
with intravenous contrast and 18FDG PET/CT, if 
necessary, were used to estimate the local efficacy, 
according to RECIST 1.1 criteria. Acute and late 
side effects were assessed by a radiation oncologist 
and recorded based on the RTOG/EORTC schema. 
Late toxicity was defined as an occurred event > 12 
weeks after PT end. 
statistical methods
Clinical endpoints were to evaluate local control 
(LC), progression-free survival (PFS), and over-
all survival (OS), measured from the time of PT 
completion (LC, OS) or the date of remission (PFS). 
Each value was calculated using the Kaplan-Meier 
method (and reverse K-M for median follow-up 
time) with analysis performed in GraphPad Prism 
8 (p-value < 0.05, assumed as statistically signifi-
cant). A log-rank test was applied to a comparison 
between analyzed factors. 
results
patient characteristics and treatment 
parameters
The median follow-up time from the finishing 
of proton re-irradiation was 21 months [range, 3 to 
25]. Patient, tumor, and treatment characteristics 
are described in Table 1. The median time from pre-
vious RT was 38 months [range, 8 to 285]. Confor-
mal prior radiotherapy received 21 patients (70%). 
None of the patients were operable, both before and 
after the PT, due to medical contraindications or re-
currence extent, or both factors. Adjuvant systemic 
treatment (i.e., chemotherapy, target, or immune 
therapy) was given to 20% (n = 6) of the patients.
Twenty-three (76.7%) of recurrent tumors were 
squamous cell carcinomas, with 13.3% (n = 4) of 
adenocarcinomas and 10% (n = 3) having neuro-
endocrine histology, all of them localized in the 
field of the first RT course. Re-irradiated sites in-
cluded: nasopharynx (n = 10, 33.4%), oral cavity 
(n = 9, 30%), parotid glands (n = 6, 20%) and 
maxillary sinuses (n = 5, 16.6%). Two patients 
(6.6%), with the longest period from the first RT 
course (126 and 285 months) and morphology 
differences from the previous diagnosis had a sec-
ondary primary tumor. According to the largest 
table 1. patient and treatment characteristics
Patient characteristics Number
Total patients 30
Median follow-up time in months 21
Gender
     Female 18 (60%) 
     Male 12 (40%)
Median age in years 62,5
Median Karnofsky score 70
Median prior rT dose in Gray 55
Median interval from initial rT in months 38
conformal prior rT 21 (70%)
Non-conformal prior rT 9 (30%)
histology
squamous cell carcinoma 23 (76.7%)
adenocarcinoma 4 (13.3%)
Neuroendocrine cancer 3 (10%)
retreatment site
aerodigestive tract 18 (60%)
skull base 12 (40%)
pT dosimetry
Median irradiated volume in cm3 158.1
Median D95 90.4
Median BeD (a/b = 10) 69.1
Median eQD2 (a/b = 10) 57.6
rT — radiotherapy; pT — proton therapy; BeD — biologically effective dose; 
eQD2 — equivalent dose
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recurrence tumor extension, all patients were also 
categorized based on anatomical site: aerodiges-
tive tract (n = 18, 60%) and skull base (n = 12, 
40%), with a view to obtain more specific report-
ing of treatment outcomes. 
The median treated tumor volume was 158.1 
cm3 [range, 13.2 to 280.1]. Despite prioritizing 
OAR-sparing over PTV coverage, the median D95 
was 90.4% [range, 85.3 to 100]. The example of the 
proton dose distribution is illustrated in Figure 1. 
Treatment outcomes of tumor control were 
assessed by regular MR imaging and clinical ex-
amination, with medical oncologists and surgeons 
enrolled. For suspicious findings, PET/CT with 
18FDG or ultrasound-guided biopsy were used. Ra-
diographic findings were described following the 
RECIST v1.1 criteria.
Tumor control and outcomes
The 1- and 2-year local control rates were 52.6% 
and 21%, respectively (Fig. 2). The median local con-
trol was 15 months. Eighteen patients (60%) have 
a locoregional recurrence. The majority of the recur-
rence (n = 15) occurred in-field/marginal, with re-
gional node metastasis observed in 3 patients (10%), 
out of the irradiated field. Only one patient (3.3%) 
had distant metastasis (in the brain stem). The 1- and 
2-year PFS rates were 21.9% and 10.9%, respectively 
(Fig. 3). The 1-year OS was 73.4%, with a rapid fall 
in the following year, with a 2-year OS rate of 8.4% 
(Fig. 4). Meanwhile, one patient had a non-cancer 
death (myocardial infarction), and one patient died 
from treatment-related late toxicity (carotid blow-
out syndrome). The median overall survival was 16 
months. The comparison between retreatment sites 
showed significant differences in the groups, with 
skull base localization associated with lower overall 
survival (hazard ratio 0.40, 95% CI: 0.1590 to 1.020; 
p = 0.03) (Fig. 5). This occurrence might be linked to 
PTV coverage decreasing to spare OARs in this com-
plicated anatomical area (SB median D95 — 91.3% 
vs. AD median D95 — 97.7%), though no significant 
correlation has been confirmed. 
Following correlation analyses of recurrent tu-
mor histology, systemic therapy, proton irradiation 
parameters (i.e., total dose, tumor volume, fraction-
ation, or time to prior RT), as much as performance 
status, gender, or age were not significantly associ-
ated with outcomes. 
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Figure 3. progression-free survival after proton re-irradiation 
(Kaplan-Meier plot)
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Treatment-related toxicity 
All of our patients tolerated proton irradiation 
well, without any treatment gaps. Radiation der-
matitis was observed in 11 patients, with 2 cases of 
grade 2 toxicity, and grade 1 in the rest. Mucositis 
grade 1–3 was recorded in 29 patients: 18 patients 
had grade 1, and in 10 cases, grade 2 toxicity oc-
curred. One patient (3.3%) experienced grade 3 
mucositis. Persisting xerostomia after initial radi-
ation therapy was observed in 100% of patients. 
Twenty patients (66.7%) additionally had chew-
ing trismus and swallowing difficulties before PT. 
Nonetheless, none of these patients described an 
increase in the symptoms after the retreatment. Se-
vere late toxicity occurred in 5 cases (16.6%): 3 
radiation-induced necrosis (including one tempo-
ral lobe damage) and one new incidence of chewing 
trismus, with one death caused (carotid bleeding), 
after three months of re-irradiation. The second 
review of treatment plans showed a possibility of 
those incidences being due to prior non-conformal 
treatment with a range of dosimetry uncertainties, 
and recurrent tumors’ growth close to OARs. No 
correlations between late toxicity and retreatment 
side were observed.     
Discussion
Thirty inoperable patients with recurrent H&N 
cancer, treated with IMPT for the second course, 
were selected for retrospective analysis. For this 
study group, we evaluated treatment efficacy and 
related toxicity using IMPT for re-irradiation. 
Locoregional recurrence after H&N therapy con-
tinues to be the most frequent pattern of failure, 
especially in locally advanced tumors, so it causes 
death in most of the cases. The highest period at 
risk is the first two years after the treatment, with 
more than 2/3 incidences [15]. Almost 15% of 
H&N patients are at risk of developing secondary 
primary cancer, with an increased incidence rate 
within long-term survival [7].
Maximal surgical resection remains the treat-
ment of choice, with 5-year OS reaching 40% [5, 
16]. Janot et al. showed in GORETEC phase III trial 
adjuvant chemoradiation improved both locore-
gional control (p < 0.0001) and disease-free survival 
(p = 0.01), without significant influence on overall 
survival (p = 0.50). However, significantly higher 
toxicity rates were observed (grade 3 in 28% cases, 
and 39% with late grade 4 complications) [17]. Nev-
ertheless, salvage surgery can only be provided for 
around 30% of all such patients. However, surgical 
success is always linked with tumor location (better 
outcomes for laryngeal cancer and neck nodes) and 
extension, alongside comorbidity [18]. For those 
patients, who are not operable, chemotherapy alone 
has only a median survival of 7.4 months, with 
relatively low impact of cetuximab addition (to 10.1 
months) [19]. It is evident that in the final results of 
most studies dedicated to the H&N re-irradiation, 
surgery plays a remarkable role. Meanwhile, our 
cohort’s poor outcomes during the second year cor-
respond to the lack of up-front surgery, as all of our 
patients were inoperable.  
Two randomized trials, RTOG 9610 [10] and 
RTOG 9911 [20], had positive outcomes combining 
RT and chemotherapy. These studies showed that 
1/3 of patients were locoregionally controlled, with 
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Figure 5. Overall survival from retreatment site. aB — aero-
digestive tract; sB — skull base; hr = 0.40, 95% cI:  
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grade 3–4 observed in around 40% of re-irradiated 
patients. At the same time, 10% of patients suffered 
from toxicity-related death.  
The most complicated re-irradiation points are 
persistence radioresistant tumor cells (even after 
high-dose RT) and reduced tissue tolerance [14, 
21, 22]. So, the main challenges in re-irradiation 
are to determine the actual tumor extent, deliver 
high doses (> 60 Gy), and spare normal tissue. In 
the last decade, IMRT-technique shows promising 
outcomes, with 32% 5-year OS, but with a severe 
toxicity risk of up to 48% [23]. However, even with 
IMRT, the high doses cannot be delivered, being 
met with OAR constraints from the previous ra-
diotherapy course. Proton therapy advantages (i.e., 
precise dose distribution, rapid dose fall, biological 
and immune features) may benefit H&N patients 
with recurrence [24]. 
In 2016, Phan et al. published the retrospective 
data about proton re-irradiation with 60 patients 
included, demonstrating 1-year OS 83.8% and 
16.7% of grade 3 late toxicity [11]. After complet-
ing PT, 58% of the patients received upfront sur-
gery, and 73% received concurrent and adjuvant 
systemic therapy, though without significant con-
sequences for the outcomes. The multi-institution-
al study by McDonald et al. included 61 patients, 
re-treated with PT for H&N recurrence or second 
primary tumor. Authors reported 2-year estimated 
OS of 32.7%, with a remarkable impact of surgery 
on outcomes: median OS with salvage surgery was 
25.1 months vs. 10.3 months without operation, 
p = 0.008. Acute grade ≥3 toxicities were seen in 
14.7% and 24.6% in the late setting, including three 
related deaths [25]. A multi-institutional report, 
published in 2016 by Romesser et al. with 91 pa-
tients involved, described a 25.1% risk of failure in 
12 months and a favorable toxicity profile. 
In our study group, we observed 73.4% of 1-year 
OS, while all of our patients could not undergo 
surgery, so the initial prognosis was relatively poor. 
The relapse patterns are in agreement with other 
studies: with mostly in-field/marginal recurrences 
and relatively low risk of distant progression [26]. 
Bulky tumors (prevailed in our cohort) or CTV > 50 
cm3 are shown to be associated with higher toxic-
ity and poor outcomes [11, 23]. Though the lower 
toxicity rate of protons is usually accounted for in 
its dose distribution, recent experimental studies 
reported lower expression of factors involved in 
lymph- and angiogenesis, inflammation, and im-
mune tolerance [27].
Adverse events from re-irradiation play a sig-
nificant role in decreasing the QoL in H&N pa-
tients. Besides, conventional radiotherapy is asso-
ciated with severe complications. Even with novel 
photon RT approaches, second irradiation still 
causes a significantly higher toxicity rate. The low 
toxicity outcomes observed in proton studies are 
promising, although longer follow-up of long-term 
survivors is necessary to estimate tissue damage 
risks related to re-irradiation. A balance between 
RT-treatment intensification and adverse events is 
quite challenging in H&N re-irradiation. The rec-
ommended re-RT dose for tumor growth control 
might be ≥ 60–66 Gy, whereas most critical OARs 
located at the H&N area could already exceed their 
limits after prior radiotherapy. Furthermore, there 
is still no consensus about dose constraints for 
re-irradiation. Chan et al. published data about 
re-irradiation of recurrent T3/T4 nasopharyngeal 
cancer, dividing OAR’s limits into absolute (i.e., 
spinal cord D1cc < 65 Gy or brain stem D1% < 78 Gy) 
and desirable cumulative doses (e.g., optic nerve 78 
Gy, temporal lobe D1cc < 84.5 Gy) [28]. In contrast, 
some authors maintain more conservative doses 
(e.g., myelon BED < 100–120 Gy) [9]. 
Generally, many patients with recurrent H&N 
cancer may not survive long enough to meet po-
tential adverse effects because of low survival 
chances. We observed only one death related to 
carotid bleeding, one of the most morbid toxici-
ties associated with re-irradiation in the head and 
neck area [29]. Nevertheless, the carotid artery dose 
constraints are used mostly for SBRT (with a value 
from 32.5 to 34.0 Gy for hypofractionation) and 
rarely assessed in a fractionated RT [30].   
As the retreatment of H&N cancers is extreme-
ly controversial and complicated, it is essential 
to define significant prognostic factors to divide 
patients into several groups, which could guide 
for therapy choice. Thus, Mattew C. et al., based 
on the results of IMRT of 412 patients, identified 
three prognostic groups: 1) >2 years from RT and 
resected tumor (2-year OS, 61.9%); 2) >2 years 
from RT and unresected tumor, in good perfor-
mance status (2-year OS, 40.0%) and 3) the rest 
of patients, who do not meet these criteria, with 
a poor prognosis (2-year, 16.8%) [31]. This classi-
fication can potentially help  better understand pa-
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tient selection for re-RT and adjuvant treatment, 
following given indicators.   
conclusion 
Although this study has a limitation in its retro-
spective nature, we demonstrate that proton beam 
therapy can be a safe and effective treatment for 
patients with recurrent H&N cancers, even with 
unresectable tumors. Proton’s physical and radio-
biological advantages provide a good compromise 
between delivering higher radiation doses and spar-
ing previously irradiated zones. We achieved an ad-
equate one-year tumor control with reasonably low 
rates of toxicity. Meanwhile, further investigations 
are required in the field of proton re-irradiation 
(e.g., flash-protons) in combination with novel sys-
temic therapy agents for intensification of adjuvant 
treatment.
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